Loading clinical trials...

GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD) | Clinical Trials | Clareo Health

TERMINATED

GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

A Study of Disease Progression in Genetically Defined Subjects With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

NCT03894020•Gyroscope Therapeutics Limited

View on ClinicalTrials.gov

Summary

An observational study to evaluate the natural progression of dry AMD in genetically defined subjects

Detailed Description

Prospective, observational study to evaluate the natural progression of anatomical and functional visual parameters in genetically defined subjects with GA due to AMD.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Adults with unilateral or bilateral Geographic Atrophy (GA) due to Age-related Macular Degeneration (AMD)
•2. BCVA of 40 letters or better using ETDRS charts

Exclusion Criteria

•1. Evidence or history of neovascular Age-related Macular Degeneration (AMD) or diabetic retinopathy
•2. Significant ocular or non-ocular disease that would impact the subject's ability to participate in the study
•3. Participation in another research study involving an investigational product within the previous 4 weeks or 5 half-lives whichever is longer from the screening/baseline OR received a gene/cell therapy at any time previously

Locations (71)

Retinal Research Institute (retina consultants of AZ)

Phoenix, Arizona, United States

Retina Centers PC

Tucson, Arizona, United States

Retina Vitreous Associates Medical Group

Beverly Hills, California, United States

Byers Eye Institute at Stanford

Palo Alto, California, United States

Retina Health Center

Fort Myers, Florida, United States

Retina Vitreous Associates of Florida

St. Petersburg, Florida, United States

Southeast Retina Center

Augusta, Georgia, United States

Georgia Retina PC

Marietta, Georgia, United States

University Retina Macula Associates PC

Lemont, Illinois, United States

Midwest Eye Institute Northside

Indianapolis, Indiana, United States

Key Dates

Start Date

January 8, 2019

Primary Completion Date

March 25, 2024

Completion Date

March 25, 2024

Last Updated

October 30, 2024

Enrollment

ACTUAL participants

Conditions

Dry Age-related Macular DegenerationMacular DegenerationRetinal DiseaseRetinal DegenerationGeographic AtrophyMacular Atrophy

Direct Discrimination of Quantum States by the Human Eye

NCT05913063

Age-Related Macular Degeneration

View study

RECRUITING

Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection

NCT07446582

Age-Related (Dry) Macular Degeneration

View study

RECRUITING

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

NCT06779773

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 30, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)

Inclusion Criteria

Exclusion Criteria

Direct Discrimination of Quantum States by the Human Eye

Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration